

Product Information

Size:

50ul

Reactivity:

Human, Mouse, Rat

Source:

Rabbit

Isotype:

IgG

Applications:

ELISA, WB, IHC

Recommended dilutions:

ELISA:1:1000-1:2000, WB:1:200-1:1000,
IHC:1:25-1:100

Protein Background:

NAD-dependent protein deacetylase. Has deacetylase activity towards histone H3K9Ac and H3K56Ac. Modulates acetylation of histone H3 in telomeric chromatin during the S-phase of the cell cycle. Deacetylates histone H3K9Ac at NF-kappa-B target promoters and may down-regulate the expression of a subset of NF-kappa-B target genes. Acts as a corepressor of the transcription factor HIF1A to control the expression of multiple glycolytic genes to regulate glucose homeostasis. Required for genomic stability. Regulates the production of TNF protein. Has a role in the regulation of life span. Deacetylation of nucleosomes interferes with RELA binding to target DNA. May be required for the association of WRN with telomeres during S-phase and for normal telomere maintenance. Required for genomic stability. Required for normal IGF1 serum levels and normal glucose homeostasis. Modulates cellular senescence and apoptosis. On DNA damage, promotes DNA end resection via deacetylation of RBBP8.

Gene ID:

CRHR2

Uniprot

Q13324

Synonyms:

corticotropin releasing hormone receptor 2


Immunogen:

Synthetic peptide of human CRHR2.

Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol


Product Images



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using PACO19510(CRHR2 Antibody) at dilution 1/25, on the right is treated with synthetic peptide. (Original magnification: x—200).



Gel: 8%SDS-PAGE, Lysate: 40 μ g, Lane 1-2: NIH/3T3 cells, mouse brain tissue, Primary antibody: PACO19510(CRHR2 Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes.



The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO19510(CRHR2 Antibody) at dilution 1/25, on the right is treated with synthetic peptide. (Original magnification: x—200).